Certificati di investimento - Cap. 4 (29 lettori)

Stato
Chiusa ad ulteriori risposte.

NoWay

It's time to play the game
Comunque chi desiderava volatilità direi che da Madame Lagarde in poi può anche considerarsi soddisfatto...
 

Fabrib

Forumer storico
Buy DE000VP7K7K3... buon PM di Biogen...

  • The FDA has extended the review period by three months for Biogen and Eisai's Biologics License Application (BLA) for aducanumab, an investigational treatment for Alzheimer’s disease.
  • The updated PDUFA action date is June 7, 2021.
  • Biogen submitted a response to an information request by the FDA, including additional analyses and clinical data, which was considered as a major amendment that will require additional time for review.
  • Biogen licensed aducanumab from Neurimmune and since October 2017, Biogen and Eisai have collaborated on the development of aducanumab globally.
  • BIIB shares up 10% premarket.
 
Stato
Chiusa ad ulteriori risposte.

Users who are viewing this thread

Alto